Expert Opinion On Drug Safety
Scope & Guideline
Empowering Researchers with Critical Drug Safety Insights
Introduction
Aims and Scopes
- Pharmacovigilance and Drug Safety Analysis:
The journal emphasizes the importance of pharmacovigilance, aiming to monitor, assess, and understand adverse drug reactions and safety signals associated with various medications. - Clinical Safety Evaluations:
It provides comprehensive evaluations of drug safety through systematic reviews, meta-analyses, and real-world studies, offering insights into the efficacy and safety of drugs across multiple therapeutic areas. - Risk-Benefit Assessments:
The journal focuses on the balance between the therapeutic benefits of drugs and their potential risks, providing guidance for clinicians in making informed treatment decisions. - Emerging Drug Safety Concerns:
It addresses new and emerging safety concerns related to drugs, particularly in the context of novel therapies and changing treatment paradigms. - Real-World Evidence Integration:
The journal integrates real-world evidence to enhance understanding of drug safety in diverse populations and clinical settings, ensuring that findings are applicable to everyday medical practice.
Trending and Emerging
- Real-World Evidence and Data Mining:
There is a growing emphasis on utilizing real-world evidence and advanced data mining techniques to uncover adverse drug reactions and safety signals, reflecting a shift towards more data-driven approaches in pharmacovigilance. - Machine Learning and Artificial Intelligence in Drug Safety:
The integration of machine learning and AI technologies in pharmacovigilance is trending, with studies focusing on their potential to improve signal detection and risk assessment in drug safety. - Patient-Centric Pharmacovigilance:
An emerging focus on incorporating patient perspectives, experiences, and reported outcomes into drug safety evaluations is evident, aiming to enhance the relevance and applicability of findings. - Safety of Novel Therapeutics and Biologics:
Research is increasingly directed towards the safety profiles of novel therapeutics, including biologics and targeted therapies, particularly in oncology and immunology, reflecting the rapid advancement of these treatment modalities. - Long-Term Safety and Post-Marketing Surveillance:
There is a heightened interest in long-term safety studies and post-marketing surveillance, emphasizing the need to monitor drugs after they have been approved and widely prescribed.
Declining or Waning
- Traditional Pharmacovigilance Methods:
There is a noticeable decline in studies focusing solely on traditional pharmacovigilance methods, as the field shifts towards more innovative and technology-driven approaches such as machine learning and big data analytics. - Generalized Drug Safety Reviews:
The trend towards more specialized and targeted safety evaluations has led to a decrease in broad, generalized reviews of drug safety, which may have been more common in earlier publications. - Historical Drug Safety Studies:
Research focusing on historical data or older medications is becoming less prevalent, as the journal increasingly prioritizes contemporary drugs and therapies. - Single-Agent Safety Studies:
There is a waning interest in studies examining the safety of single-agent therapies, with a growing focus on combination therapies and polypharmacy, especially in complex patient populations. - Pharmacovigilance in Non-Pharmaceutical Contexts:
The journal has seen a reduction in articles addressing pharmacovigilance in non-pharmaceutical contexts, such as dietary supplements or herbal products, which were previously more common.
Similar Journals
AMERICAN JOURNAL OF THERAPEUTICS
Advancing Therapeutic Knowledge for a Healthier TomorrowThe American Journal of Therapeutics is a prominent academic journal published by Lippincott Williams & Wilkins, specializing in the fields of medicine and pharmacology. With a rich history originating from 1960 and a commitment to advancing therapeutic knowledge through peer-reviewed research, this journal serves as a vital resource for professionals, researchers, and students alike. Its strong impact factor, alongside its classification in the Q2 and Q3 quartiles for diverse categories in medicine and pharmacology, underscores its significance in the academic community. The journal engages with the latest findings and innovations in therapeutic approaches, offering a platform for discussion and dissemination of research that addresses critical healthcare challenges. Although it operates under a traditional subscription model, the journal aims to foster open discourse within the therapeutic landscape, making it essential reading for those dedicated to enhancing patient care and pharmaceutical practices.
Drug Healthcare and Patient Safety
Fostering global discourse on drug healthcare advancements.Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.
CLINICAL DRUG INVESTIGATION
Elevating standards in clinical drug studies.CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Advancing knowledge in pharmacology and public health.Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.
International Journal of Clinical Pharmacy
Unlocking the Future of Pharmacy through Open Access ResearchThe International Journal of Clinical Pharmacy, published by Springer, serves as a pivotal platform for advancing research in the fields of Pharmaceutical Science and Pharmacology. This esteemed journal, recognized for its significant impact with an impressive Q1 ranking in Pharmacy and multiple Q2 designations, provides a dedicated space for scholars and practitioners to share innovative findings and methodologies that enhance clinical pharmacy practices. With an international reach and publication spanning from 2011 to 2024, the journal aims to facilitate knowledge exchange among researchers, professionals, and students, ultimately contributing to improved therapeutic outcomes. As an open-access journal, it promotes widespread dissemination of vital research, ensuring that cutting-edge clinical pharmacy knowledge is accessible to all stakeholders in the healthcare continuum.
Therapeutic Advances in Drug Safety
Bridging Pharmacological Innovation and Clinical ExcellenceTherapeutic Advances in Drug Safety is a prestigious open-access journal published by SAGE Publications Ltd that has made significant strides in the field of pharmacology since its inception in 2010. With an impressive impact factor that places it in the Q1 category for Pharmacology (medical), this journal ranks 61st out of 272 in Scopus, showcasing its global influence and commitment to advancing drug safety research. Based in the United Kingdom, it aims to bridge the critical gap between pharmacological innovation and clinical application, offering a platform for the dissemination of groundbreaking research, case studies, and expert reviews. Since adopting an Open Access model in 2019, the journal has significantly increased its reach, ensuring that vital findings in drug safety are accessible to researchers, healthcare professionals, and educators worldwide. As the field of drug safety continues to evolve, Therapeutic Advances in Drug Safety remains an essential resource for those dedicated to enhancing safe therapeutic practices and patient outcomes.
Current Drug Safety
Navigating the Complexities of Pharmacological SafetyCurrent Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.
DRUGS
Leading the Charge in Medical PharmacologyDRUGS is a prestigious, peer-reviewed journal published by ADIS INT LTD, specializing in the field of pharmacology across diverse medical applications. With an impressive impact factor and ranking as Q1 in the Pharmacology (Medical) category as per the 2023 metrics, this journal consistently exhibits a strong influence in the medical research community, holding a notable rank of #3 out of 272 in its domain on Scopus, placing it within the 99th percentile. Established in 1971 and converging its insightful contributions until 2024, DRUGS encompasses a broad scope, focusing on the latest advancements in drug research, development, and clinical applications, aiming to bridge the gap between laboratory discoveries and therapeutic practices. Though not an Open Access journal, it remains a key resource for researchers, professionals, and students keen on exploring cutting-edge findings and developments in pharmacology. Its location in the United Kingdom further emphasizes its role as a global leader in pharmaceutical sciences.
European Journal of Hospital Pharmacy
Navigating the Future of Pharmacy in Hospital SettingsThe European Journal of Hospital Pharmacy, published by the prestigious BMJ PUBLISHING GROUP, stands as a vital resource in the field of pharmacy, specifically focused on practices within hospital settings. With its ISSN 2047-9956 and E-ISSN 2047-9964, this journal provides an essential platform for researchers, practitioners, and students to disseminate and access high-quality research that influences clinical practice. Recognized for its significant impact, the journal has achieved a commendable Q2 ranking in both the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and Pharmacy categories according to Scopus, highlighting its status within the academic community. The journal is indexed among the top 18% in its category, showcasing innovative research and advancements in the field. While the European Journal of Hospital Pharmacy does not operate under an open-access model, its deep commitment to enhancing pharmaceutical care within European hospital settings remains undeterred. The journal also covers a converged period from 2010 to 2024, providing comprehensive insights into evolving practices and challenges. As a premier publication, it plays an essential role in education and professional development, making it indispensable for those involved in pharmacy and healthcare.
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Elevating Knowledge in Medicine and Drug InnovationBIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.